0.0002EUR0.00%Mkt Cap: 95 EURP/E: —Last update: 2026-05-14
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune disea…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)0.00
PEG—
P/B0.00
P/S0.00
EV/EBITDA-0.02
EV/Revenue0.66
EPS (TTM)-221.36
EPS (Forward)0.10
Cash Flow & Leverage
FCF Yield-4024443.16%
FCF Margin-1918.64%
Operating CF-3.60M EUR
CapEx (TTM)79.71K EUR
Net Debt/EBITDA-0.02
Net Debt132.15K EUR
Technical
SMA 500.0006 (-63.8%)
SMA 2000.1261 (-99.8%)
Beta42.06
S&P 52W Chg24.23%
Avg Vol (30d)58.98M
Avg Vol (10d)72.93M
Technical Indicators
RSI (14)26.1
MACD-0.0001
MACD Signal-0.0002
MACD Hist.+0.0000
BB Upper0.0004 EUR
BB Middle0.0003 EUR
BB Lower0.0001 EUR
BB Width144.67%
ATR (14)0.0002 EUR
Vol Ratio (20d)0.38x
52W Range
0.00020% of range6.600
52W High6.600 EUR
52W Low0.0002 EUR
Profitability
Gross Margin11.58%
EBITDA Margin0.00%
Profit Margin-8984.51%
Oper. Margin-1683.64%
ROE-182.23%
ROA-149.13%
Revenue Growth-59.80%
Earnings Growth—
Balance Sheet
Debt/Equity0.01
Current Ratio0.67
Quick Ratio0.65
Book Value/Sh39.63 EUR
Cash/Share0.0810 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:1000
Split DateJul 21, 2025
Ownership
Shares Out.476.63K
Float—
Insiders0.00%
Institutions0.00%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap95 EUR
Enterprise Value132.25K EUR
Revenue (TTM)199.27K EUR
Gross Profit42.42K EUR
Net Income (TTM)-32.91M EUR
Revenue/Share0.4180 EUR
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees16
Last Price0.0002 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR00140077X1